| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 87 | 2024 | 669 | 10.550 |
Why?
|
| Pancreatectomy | 38 | 2024 | 159 | 4.470 |
Why?
|
| Psoriasis | 14 | 2020 | 245 | 4.200 |
Why?
|
| Adenocarcinoma | 46 | 2024 | 1194 | 3.920 |
Why?
|
| Carcinoma, Pancreatic Ductal | 22 | 2024 | 112 | 3.690 |
Why?
|
| Pancreaticoduodenectomy | 24 | 2023 | 83 | 3.260 |
Why?
|
| Dermatologic Agents | 7 | 2019 | 73 | 2.380 |
Why?
|
| Liver Neoplasms | 17 | 2024 | 758 | 1.820 |
Why?
|
| Laparoscopy | 18 | 2023 | 773 | 1.670 |
Why?
|
| HLA-C Antigens | 3 | 2017 | 17 | 1.580 |
Why?
|
| Aged | 112 | 2024 | 19165 | 1.540 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2021 | 969 | 1.490 |
Why?
|
| Ustekinumab | 4 | 2019 | 51 | 1.470 |
Why?
|
| Middle Aged | 115 | 2024 | 25974 | 1.440 |
Why?
|
| Neuroendocrine Tumors | 9 | 2023 | 118 | 1.390 |
Why?
|
| Robotic Surgical Procedures | 11 | 2024 | 306 | 1.380 |
Why?
|
| Humans | 205 | 2024 | 89357 | 1.280 |
Why?
|
| Neoplasm Staging | 33 | 2018 | 2018 | 1.280 |
Why?
|
| Postoperative Complications | 21 | 2024 | 2284 | 1.250 |
Why?
|
| Antibodies, Monoclonal | 9 | 2018 | 1412 | 1.220 |
Why?
|
| Bile Duct Neoplasms | 4 | 2021 | 90 | 1.170 |
Why?
|
| Pancreatic Fistula | 7 | 2023 | 17 | 1.150 |
Why?
|
| Male | 125 | 2024 | 42411 | 1.150 |
Why?
|
| Female | 126 | 2024 | 46202 | 1.100 |
Why?
|
| Carcinoma | 7 | 2012 | 443 | 1.100 |
Why?
|
| Retrospective Studies | 61 | 2024 | 9057 | 1.070 |
Why?
|
| Treatment Outcome | 51 | 2024 | 8241 | 1.030 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2012 | 33 | 1.010 |
Why?
|
| Colorectal Neoplasms | 13 | 2023 | 981 | 1.010 |
Why?
|
| Hepatectomy | 9 | 2024 | 170 | 0.980 |
Why?
|
| Interleukin-17 | 3 | 2020 | 105 | 0.970 |
Why?
|
| Venous Thromboembolism | 3 | 2023 | 159 | 0.910 |
Why?
|
| Deoxycytidine | 10 | 2018 | 238 | 0.910 |
Why?
|
| General Surgery | 3 | 2024 | 236 | 0.900 |
Why?
|
| Ampulla of Vater | 4 | 2014 | 23 | 0.870 |
Why?
|
| Aged, 80 and over | 39 | 2024 | 6811 | 0.840 |
Why?
|
| Adult | 64 | 2024 | 26607 | 0.830 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2023 | 2566 | 0.790 |
Why?
|
| Portal Vein | 2 | 2021 | 120 | 0.780 |
Why?
|
| Endosonography | 3 | 2015 | 98 | 0.760 |
Why?
|
| Pancreatic Diseases | 4 | 2020 | 53 | 0.760 |
Why?
|
| Length of Stay | 10 | 2024 | 736 | 0.760 |
Why?
|
| Survival Analysis | 25 | 2017 | 1534 | 0.750 |
Why?
|
| Pancreatic Cyst | 5 | 2009 | 28 | 0.730 |
Why?
|
| Rectal Neoplasms | 5 | 2007 | 127 | 0.720 |
Why?
|
| Thrombosis | 2 | 2023 | 302 | 0.710 |
Why?
|
| Biological Therapy | 1 | 2020 | 47 | 0.700 |
Why?
|
| Organizational Innovation | 2 | 2020 | 41 | 0.690 |
Why?
|
| Neoadjuvant Therapy | 11 | 2016 | 377 | 0.690 |
Why?
|
| Drug Eruptions | 1 | 2020 | 34 | 0.690 |
Why?
|
| Acrodermatitis | 1 | 2019 | 4 | 0.670 |
Why?
|
| Stents | 4 | 2021 | 405 | 0.660 |
Why?
|
| Societies, Medical | 3 | 2020 | 575 | 0.650 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 71 | 0.630 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 253 | 0.630 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 1840 | 0.630 |
Why?
|
| Postoperative Hemorrhage | 3 | 2017 | 46 | 0.620 |
Why?
|
| Stomach Neoplasms | 5 | 2016 | 282 | 0.620 |
Why?
|
| Adalimumab | 2 | 2018 | 86 | 0.620 |
Why?
|
| Surgical Wound Infection | 4 | 2023 | 201 | 0.610 |
Why?
|
| Prognosis | 27 | 2024 | 3783 | 0.600 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 276 | 0.590 |
Why?
|
| Drainage | 3 | 2015 | 162 | 0.580 |
Why?
|
| Survival Rate | 24 | 2018 | 1901 | 0.580 |
Why?
|
| Lymph Node Excision | 8 | 2016 | 220 | 0.570 |
Why?
|
| Cholangiocarcinoma | 4 | 2021 | 76 | 0.560 |
Why?
|
| Colonic Neoplasms | 9 | 2021 | 573 | 0.550 |
Why?
|
| Dermatitis, Atopic | 2 | 2021 | 55 | 0.540 |
Why?
|
| Preoperative Care | 8 | 2017 | 396 | 0.540 |
Why?
|
| Alleles | 2 | 2017 | 1135 | 0.530 |
Why?
|
| Pancreatitis | 5 | 2015 | 86 | 0.530 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2007 | 48 | 0.530 |
Why?
|
| Biomarkers, Tumor | 12 | 2024 | 1549 | 0.520 |
Why?
|
| Learning | 1 | 2019 | 285 | 0.520 |
Why?
|
| Education, Medical | 1 | 2019 | 243 | 0.520 |
Why?
|
| Pancreas | 8 | 2023 | 246 | 0.510 |
Why?
|
| Intestinal Neoplasms | 2 | 2009 | 64 | 0.500 |
Why?
|
| Risk Factors | 23 | 2023 | 5499 | 0.500 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2018 | 244 | 0.490 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2017 | 487 | 0.490 |
Why?
|
| Mass Screening | 2 | 2015 | 636 | 0.490 |
Why?
|
| Radiotherapy, Adjuvant | 12 | 2018 | 296 | 0.490 |
Why?
|
| Mesenteric Veins | 4 | 2021 | 33 | 0.490 |
Why?
|
| Regional Health Planning | 2 | 2014 | 13 | 0.480 |
Why?
|
| Embolization, Therapeutic | 2 | 2014 | 262 | 0.470 |
Why?
|
| Hepatic Artery | 1 | 2014 | 84 | 0.460 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 98 | 0.460 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2013 | 6 | 0.450 |
Why?
|
| Carcinoma, Papillary | 4 | 2007 | 159 | 0.450 |
Why?
|
| Registries | 6 | 2017 | 784 | 0.450 |
Why?
|
| Combined Modality Therapy | 16 | 2016 | 1719 | 0.450 |
Why?
|
| Patient Readmission | 4 | 2017 | 352 | 0.430 |
Why?
|
| United States | 29 | 2024 | 6989 | 0.420 |
Why?
|
| Prospective Studies | 10 | 2023 | 4289 | 0.410 |
Why?
|
| Databases, Factual | 10 | 2017 | 856 | 0.410 |
Why?
|
| Proportional Hazards Models | 11 | 2017 | 851 | 0.410 |
Why?
|
| Barrett Esophagus | 5 | 2018 | 93 | 0.400 |
Why?
|
| Cohort Studies | 11 | 2020 | 2872 | 0.390 |
Why?
|
| Quality Indicators, Health Care | 2 | 2010 | 146 | 0.390 |
Why?
|
| Early Detection of Cancer | 2 | 2015 | 416 | 0.390 |
Why?
|
| Radiotherapy, Conformal | 2 | 2011 | 84 | 0.390 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2011 | 2 | 0.390 |
Why?
|
| Lymph Nodes | 7 | 2016 | 548 | 0.380 |
Why?
|
| Esophageal Neoplasms | 8 | 2018 | 332 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2018 | 394 | 0.360 |
Why?
|
| Withholding Treatment | 1 | 2011 | 117 | 0.350 |
Why?
|
| Young Adult | 12 | 2021 | 6312 | 0.350 |
Why?
|
| Neoplasms | 9 | 2023 | 3041 | 0.350 |
Why?
|
| SEER Program | 3 | 2014 | 197 | 0.350 |
Why?
|
| Health Care Costs | 2 | 2017 | 235 | 0.350 |
Why?
|
| Carcinoid Tumor | 4 | 2002 | 45 | 0.350 |
Why?
|
| Follow-Up Studies | 16 | 2018 | 3666 | 0.340 |
Why?
|
| Surgeons | 3 | 2023 | 248 | 0.340 |
Why?
|
| Internship and Residency | 3 | 2024 | 1045 | 0.340 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2024 | 253 | 0.340 |
Why?
|
| Quality of Health Care | 2 | 2010 | 385 | 0.330 |
Why?
|
| Intestine, Small | 2 | 2009 | 299 | 0.320 |
Why?
|
| Logistic Models | 9 | 2020 | 1213 | 0.320 |
Why?
|
| Multivariate Analysis | 9 | 2019 | 988 | 0.310 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2018 | 157 | 0.310 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 181 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 317 | 0.300 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 21 | 0.300 |
Why?
|
| Hospital Bed Capacity | 1 | 2007 | 20 | 0.300 |
Why?
|
| Age Factors | 5 | 2018 | 1870 | 0.290 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1242 | 0.290 |
Why?
|
| Incidence | 10 | 2022 | 1595 | 0.280 |
Why?
|
| Quality Improvement | 2 | 2024 | 451 | 0.280 |
Why?
|
| Hospitals | 5 | 2019 | 299 | 0.280 |
Why?
|
| Patient Selection | 4 | 2014 | 684 | 0.270 |
Why?
|
| Cholangitis | 1 | 2006 | 19 | 0.270 |
Why?
|
| Hospital Costs | 3 | 2017 | 109 | 0.270 |
Why?
|
| Fluorouracil | 10 | 2023 | 561 | 0.260 |
Why?
|
| Time Factors | 9 | 2018 | 5338 | 0.260 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2005 | 25 | 0.260 |
Why?
|
| Mutation | 5 | 2024 | 4143 | 0.250 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 435 | 0.250 |
Why?
|
| Gastrectomy | 2 | 2016 | 69 | 0.250 |
Why?
|
| Simulation Training | 2 | 2024 | 97 | 0.250 |
Why?
|
| Disposable Equipment | 2 | 2015 | 21 | 0.240 |
Why?
|
| Curriculum | 3 | 2024 | 568 | 0.240 |
Why?
|
| Risk Assessment | 5 | 2019 | 2303 | 0.240 |
Why?
|
| Skin | 2 | 2020 | 582 | 0.240 |
Why?
|
| CA-19-9 Antigen | 3 | 2014 | 12 | 0.240 |
Why?
|
| Clinical Competence | 4 | 2024 | 784 | 0.240 |
Why?
|
| Hospitals, Community | 3 | 2010 | 32 | 0.240 |
Why?
|
| Liver Transplantation | 3 | 2018 | 1180 | 0.240 |
Why?
|
| Gallbladder Neoplasms | 2 | 2020 | 23 | 0.230 |
Why?
|
| Virtual Reality | 1 | 2024 | 24 | 0.230 |
Why?
|
| Drug Administration Schedule | 6 | 2017 | 895 | 0.230 |
Why?
|
| MicroRNAs | 2 | 2023 | 551 | 0.230 |
Why?
|
| Insurance Claim Review | 1 | 2004 | 45 | 0.230 |
Why?
|
| Rectum | 1 | 2004 | 148 | 0.230 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 48 | 0.220 |
Why?
|
| Cefoxitin | 1 | 2023 | 3 | 0.220 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2023 | 11 | 0.220 |
Why?
|
| Esophagectomy | 3 | 2012 | 92 | 0.220 |
Why?
|
| Chemoradiotherapy | 3 | 2016 | 309 | 0.220 |
Why?
|
| Rectus Abdominis | 2 | 2017 | 40 | 0.220 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2023 | 16 | 0.220 |
Why?
|
| Benzoates | 4 | 2007 | 33 | 0.220 |
Why?
|
| Mortality | 1 | 2004 | 149 | 0.210 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 975 | 0.210 |
Why?
|
| Frailty | 1 | 2024 | 76 | 0.210 |
Why?
|
| Bevacizumab | 3 | 2018 | 289 | 0.210 |
Why?
|
| Chronic Disease | 3 | 2020 | 950 | 0.210 |
Why?
|
| Diagnosis, Differential | 6 | 2015 | 1597 | 0.210 |
Why?
|
| Cecal Neoplasms | 1 | 2002 | 5 | 0.200 |
Why?
|
| Biliary Tract Diseases | 1 | 2022 | 36 | 0.200 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 1109 | 0.200 |
Why?
|
| Ileal Neoplasms | 1 | 2002 | 9 | 0.200 |
Why?
|
| Anus Neoplasms | 3 | 2011 | 36 | 0.200 |
Why?
|
| Genotype | 2 | 2017 | 1849 | 0.200 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2001 | 7 | 0.200 |
Why?
|
| Endoscopy, Digestive System | 2 | 2012 | 68 | 0.200 |
Why?
|
| Italy | 2 | 2020 | 108 | 0.200 |
Why?
|
| Bile Ducts, Extrahepatic | 2 | 2012 | 11 | 0.200 |
Why?
|
| Algorithms | 4 | 2018 | 1877 | 0.200 |
Why?
|
| Gastric Bypass | 1 | 2023 | 110 | 0.200 |
Why?
|
| Situs Inversus | 1 | 2001 | 15 | 0.200 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2018 | 35 | 0.190 |
Why?
|
| Obesity, Morbid | 2 | 2023 | 233 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2010 | 1265 | 0.190 |
Why?
|
| Infliximab | 3 | 2018 | 159 | 0.190 |
Why?
|
| Eczema | 1 | 2021 | 7 | 0.190 |
Why?
|
| Anastomosis, Surgical | 5 | 2016 | 273 | 0.190 |
Why?
|
| Sigmoidoscopy | 1 | 2001 | 36 | 0.190 |
Why?
|
| Palliative Care | 5 | 2007 | 264 | 0.190 |
Why?
|
| Models, Theoretical | 1 | 2004 | 491 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2017 | 2661 | 0.180 |
Why?
|
| Nurse Practitioners | 1 | 2001 | 30 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 481 | 0.180 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 56 | 0.180 |
Why?
|
| Cell Cycle | 3 | 2007 | 509 | 0.180 |
Why?
|
| Adolescent | 12 | 2021 | 9263 | 0.180 |
Why?
|
| Drug Substitution | 2 | 2018 | 26 | 0.180 |
Why?
|
| Etanercept | 2 | 2018 | 33 | 0.180 |
Why?
|
| Thyroid Neoplasms | 4 | 2020 | 424 | 0.180 |
Why?
|
| Europe | 2 | 2019 | 321 | 0.180 |
Why?
|
| Genetic Markers | 3 | 2017 | 478 | 0.180 |
Why?
|
| Surgical Oncology | 1 | 2020 | 27 | 0.170 |
Why?
|
| Robotics | 1 | 2023 | 269 | 0.170 |
Why?
|
| Chemoembolization, Therapeutic | 4 | 2009 | 35 | 0.170 |
Why?
|
| Biological Products | 2 | 2013 | 155 | 0.170 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 115 | 0.170 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2001 | 112 | 0.170 |
Why?
|
| Emergencies | 1 | 2020 | 121 | 0.170 |
Why?
|
| Colonic Polyps | 2 | 2008 | 132 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2020 | 60 | 0.170 |
Why?
|
| Cancer Care Facilities | 2 | 2010 | 29 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 6 | 2012 | 576 | 0.170 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 66 | 0.170 |
Why?
|
| Lymphatic Metastasis | 8 | 2008 | 502 | 0.170 |
Why?
|
| Sepsis | 1 | 2023 | 321 | 0.170 |
Why?
|
| Cell Proliferation | 6 | 2008 | 1652 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 860 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2020 | 187 | 0.160 |
Why?
|
| Arachidonate 5-Lipoxygenase | 3 | 2008 | 22 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 339 | 0.160 |
Why?
|
| Steroids | 1 | 2020 | 174 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 122 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2014 | 1365 | 0.160 |
Why?
|
| Yttrium Radioisotopes | 2 | 2009 | 58 | 0.160 |
Why?
|
| Education, Medical, Continuing | 2 | 2015 | 105 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 1997 | 159 | 0.150 |
Why?
|
| Conversion to Open Surgery | 1 | 2018 | 11 | 0.150 |
Why?
|
| Propensity Score | 4 | 2020 | 147 | 0.150 |
Why?
|
| Radiotherapy | 4 | 2012 | 333 | 0.150 |
Why?
|
| Comorbidity | 3 | 2021 | 949 | 0.150 |
Why?
|
| Adenoma | 3 | 2008 | 246 | 0.150 |
Why?
|
| Liver | 2 | 2017 | 1208 | 0.150 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1431 | 0.150 |
Why?
|
| Thyroidectomy | 3 | 2007 | 171 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2018 | 134 | 0.150 |
Why?
|
| Carcinoma in Situ | 2 | 2005 | 53 | 0.150 |
Why?
|
| Reoperation | 3 | 2017 | 599 | 0.150 |
Why?
|
| Databases as Topic | 2 | 2007 | 94 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 164 | 0.150 |
Why?
|
| Receptors, Calcitriol | 1 | 2018 | 130 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 1999 | 726 | 0.140 |
Why?
|
| Stromal Cells | 2 | 2015 | 151 | 0.140 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 1723 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2018 | 123 | 0.140 |
Why?
|
| Laparotomy | 1 | 2017 | 67 | 0.140 |
Why?
|
| Dyslipidemias | 1 | 2018 | 107 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 433 | 0.140 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2016 | 10 | 0.140 |
Why?
|
| Abdominal Wall | 1 | 2017 | 30 | 0.140 |
Why?
|
| Incidental Findings | 1 | 2017 | 98 | 0.140 |
Why?
|
| Pylorus | 2 | 2007 | 14 | 0.140 |
Why?
|
| Muscular Atrophy | 1 | 2017 | 46 | 0.140 |
Why?
|
| Stomach | 2 | 2012 | 111 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 149 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 1072 | 0.140 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 2 | 1993 | 12 | 0.140 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 2415 | 0.140 |
Why?
|
| Electric Impedance | 1 | 2016 | 110 | 0.140 |
Why?
|
| Guideline Adherence | 4 | 2017 | 230 | 0.130 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 1214 | 0.130 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2006 | 137 | 0.130 |
Why?
|
| Cell Line, Tumor | 10 | 2018 | 2558 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2016 | 232 | 0.130 |
Why?
|
| Lymphoma | 2 | 2002 | 265 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 2 | 2015 | 122 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.120 |
Why?
|
| Academic Medical Centers | 2 | 2007 | 385 | 0.120 |
Why?
|
| Benchmarking | 2 | 2008 | 79 | 0.120 |
Why?
|
| Cell Division | 6 | 2007 | 696 | 0.120 |
Why?
|
| Feasibility Studies | 4 | 2016 | 780 | 0.120 |
Why?
|
| Membrane Proteins | 4 | 2005 | 1224 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2014 | 53 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2014 | 56 | 0.120 |
Why?
|
| Gene Frequency | 1 | 2016 | 685 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2005 | 226 | 0.120 |
Why?
|
| Hernia, Inguinal | 1 | 2015 | 74 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 2340 | 0.110 |
Why?
|
| Herniorrhaphy | 1 | 2015 | 91 | 0.110 |
Why?
|
| Operating Rooms | 1 | 2014 | 129 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 3448 | 0.110 |
Why?
|
| Neutropenia | 2 | 2011 | 216 | 0.110 |
Why?
|
| Margins of Excision | 3 | 2018 | 39 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 461 | 0.110 |
Why?
|
| Trisaccharides | 1 | 2012 | 12 | 0.110 |
Why?
|
| Interleukin-23 | 1 | 2013 | 57 | 0.110 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 15 | 0.110 |
Why?
|
| Interleukin-12 | 1 | 2013 | 109 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1047 | 0.100 |
Why?
|
| Quality Control | 1 | 2012 | 117 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2014 | 280 | 0.100 |
Why?
|
| Jaundice, Obstructive | 1 | 2012 | 10 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1993 | 401 | 0.100 |
Why?
|
| Nausea | 2 | 2011 | 176 | 0.100 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 193 | 0.100 |
Why?
|
| Hypertension | 1 | 2018 | 745 | 0.100 |
Why?
|
| Gallbladder | 1 | 2012 | 31 | 0.100 |
Why?
|
| Adipocytes, White | 1 | 2012 | 3 | 0.100 |
Why?
|
| Ischemic Preconditioning | 1 | 2012 | 37 | 0.100 |
Why?
|
| Electroporation | 1 | 2012 | 57 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2013 | 342 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1993 | 307 | 0.100 |
Why?
|
| Organoplatinum Compounds | 3 | 2017 | 97 | 0.100 |
Why?
|
| Serpins | 1 | 2012 | 31 | 0.100 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 72 | 0.100 |
Why?
|
| Leucovorin | 3 | 2017 | 224 | 0.100 |
Why?
|
| Arthritis, Psoriatic | 1 | 2012 | 34 | 0.100 |
Why?
|
| Ablation Techniques | 1 | 2012 | 36 | 0.100 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 119 | 0.100 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 63 | 0.100 |
Why?
|
| Esophagus | 1 | 2012 | 106 | 0.100 |
Why?
|
| Operative Time | 3 | 2017 | 143 | 0.100 |
Why?
|
| Sex Factors | 4 | 2014 | 1066 | 0.100 |
Why?
|
| Radiology, Interventional | 1 | 2012 | 69 | 0.100 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 2008 | 33 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 123 | 0.100 |
Why?
|
| Disease Progression | 5 | 2018 | 1489 | 0.100 |
Why?
|
| Photochemotherapy | 1 | 2012 | 101 | 0.100 |
Why?
|
| Arteries | 1 | 2012 | 180 | 0.100 |
Why?
|
| Microspheres | 2 | 2009 | 108 | 0.100 |
Why?
|
| Leukopenia | 1 | 2011 | 66 | 0.100 |
Why?
|
| Ileus | 1 | 2011 | 9 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 160 | 0.100 |
Why?
|
| Camptothecin | 3 | 2017 | 196 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1150 | 0.090 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 22 | 0.090 |
Why?
|
| Brachytherapy | 1 | 2012 | 121 | 0.090 |
Why?
|
| Biopsy | 5 | 2009 | 1184 | 0.090 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 54 | 0.090 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 390 | 0.090 |
Why?
|
| Methotrexate | 1 | 2011 | 250 | 0.090 |
Why?
|
| Immunohistochemistry | 9 | 2009 | 1799 | 0.090 |
Why?
|
| Receptors, Leukotriene B4 | 2 | 2007 | 6 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2009 | 287 | 0.090 |
Why?
|
| Endoscopy | 2 | 2022 | 350 | 0.090 |
Why?
|
| Intestinal Obstruction | 1 | 2011 | 89 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2011 | 237 | 0.090 |
Why?
|
| Blood Transfusion | 2 | 2024 | 169 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 103 | 0.090 |
Why?
|
| G2 Phase | 2 | 2006 | 34 | 0.090 |
Why?
|
| Mucin 5AC | 1 | 2009 | 8 | 0.090 |
Why?
|
| Mucin-2 | 1 | 2009 | 12 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 414 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 242 | 0.090 |
Why?
|
| Spleen | 1 | 2011 | 433 | 0.090 |
Why?
|
| Mucin-1 | 1 | 2009 | 45 | 0.090 |
Why?
|
| Waiting Lists | 1 | 2011 | 184 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 266 | 0.090 |
Why?
|
| Pancreatic Ducts | 2 | 1999 | 28 | 0.090 |
Why?
|
| Learning Curve | 2 | 2022 | 19 | 0.090 |
Why?
|
| Pancreatitis, Chronic | 1 | 2010 | 54 | 0.080 |
Why?
|
| Duodenal Neoplasms | 1 | 2009 | 19 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 825 | 0.080 |
Why?
|
| Sarcoma | 2 | 2002 | 220 | 0.080 |
Why?
|
| Vitamin D | 3 | 2018 | 269 | 0.080 |
Why?
|
| Safety | 2 | 2010 | 149 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 2 | 2010 | 272 | 0.080 |
Why?
|
| Remission Induction | 1 | 2011 | 740 | 0.080 |
Why?
|
| Radiotherapy Dosage | 2 | 2011 | 470 | 0.080 |
Why?
|
| Illinois | 3 | 2015 | 480 | 0.080 |
Why?
|
| Ischemia | 1 | 2011 | 251 | 0.080 |
Why?
|
| DNA Methylation | 3 | 2010 | 657 | 0.080 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2008 | 12 | 0.080 |
Why?
|
| S Phase | 2 | 2007 | 63 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 1999 | 3011 | 0.080 |
Why?
|
| Animals | 11 | 2016 | 27371 | 0.080 |
Why?
|
| Research Design | 3 | 2009 | 599 | 0.080 |
Why?
|
| Chicago | 2 | 2020 | 1427 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2008 | 34 | 0.080 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 20 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 588 | 0.080 |
Why?
|
| Esophagogastric Junction | 1 | 2008 | 34 | 0.080 |
Why?
|
| Gastroscopy | 1 | 2007 | 25 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2008 | 72 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 479 | 0.080 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2008 | 62 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 23 | 0.070 |
Why?
|
| Apoptosis | 4 | 2008 | 1717 | 0.070 |
Why?
|
| Leukotriene Antagonists | 1 | 2007 | 25 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2010 | 253 | 0.070 |
Why?
|
| Apigenin | 1 | 2006 | 7 | 0.070 |
Why?
|
| Hemothorax | 1 | 1987 | 15 | 0.070 |
Why?
|
| Stilbenes | 1 | 2007 | 25 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2010 | 341 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 1942 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 118 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 2366 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 225 | 0.070 |
Why?
|
| Workload | 2 | 2023 | 129 | 0.070 |
Why?
|
| Adenoma, Islet Cell | 2 | 2007 | 28 | 0.070 |
Why?
|
| Mitosis | 1 | 2006 | 152 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 127 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 160 | 0.070 |
Why?
|
| Leukotriene B4 | 1 | 2005 | 14 | 0.070 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 16 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2006 | 30 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2007 | 231 | 0.070 |
Why?
|
| Surgical Flaps | 1 | 2008 | 249 | 0.070 |
Why?
|
| Epithelium | 1 | 2006 | 325 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2012 | 712 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2007 | 683 | 0.060 |
Why?
|
| Cystadenocarcinoma | 2 | 1995 | 12 | 0.060 |
Why?
|
| Phosphorylation | 4 | 2006 | 1132 | 0.060 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 196 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2012 | 794 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 99 | 0.060 |
Why?
|
| Reference Values | 2 | 1999 | 661 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2017 | 231 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 277 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 18 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 160 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 196 | 0.060 |
Why?
|
| Actuarial Analysis | 2 | 2002 | 66 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 267 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2005 | 306 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2017 | 871 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 217 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 299 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2008 | 36 | 0.060 |
Why?
|
| Melanoma | 1 | 2008 | 468 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2004 | 128 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2018 | 2017 | 0.060 |
Why?
|
| Factor V | 1 | 2023 | 10 | 0.060 |
Why?
|
| Prothrombin | 1 | 2023 | 17 | 0.060 |
Why?
|
| Piperacillin | 1 | 2023 | 7 | 0.060 |
Why?
|
| Penicillanic Acid | 1 | 2023 | 11 | 0.060 |
Why?
|
| Radiography | 1 | 2005 | 809 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 2023 | 21 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 183 | 0.050 |
Why?
|
| Capillaries | 1 | 2003 | 90 | 0.050 |
Why?
|
| Protein Kinases | 2 | 1996 | 213 | 0.050 |
Why?
|
| Social Class | 1 | 2004 | 136 | 0.050 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2023 | 26 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2006 | 1862 | 0.050 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2024 | 83 | 0.050 |
Why?
|
| Cyclin A | 3 | 2007 | 29 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 580 | 0.050 |
Why?
|
| Hyaluronan Receptors | 1 | 2002 | 38 | 0.050 |
Why?
|
| Hyperparathyroidism | 1 | 2002 | 67 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2022 | 30 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2023 | 76 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1999 | 40 | 0.050 |
Why?
|
| Colectomy | 3 | 2008 | 172 | 0.050 |
Why?
|
| Parathyroid Neoplasms | 1 | 2002 | 57 | 0.050 |
Why?
|
| Parathyroidectomy | 1 | 2002 | 77 | 0.050 |
Why?
|
| Bile | 1 | 2022 | 57 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2017 | 590 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2008 | 306 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1987 | 475 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 329 | 0.050 |
Why?
|
| Cadherins | 1 | 2002 | 163 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2009 | 233 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2006 | 401 | 0.050 |
Why?
|
| Thymidylate Synthase | 1 | 2001 | 13 | 0.050 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2001 | 66 | 0.050 |
Why?
|
| Credentialing | 1 | 2001 | 14 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 356 | 0.050 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2001 | 23 | 0.050 |
Why?
|
| Marketing of Health Services | 1 | 2001 | 15 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 2006 | 268 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2001 | 82 | 0.050 |
Why?
|
| Cisplatin | 3 | 2011 | 618 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 164 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 188 | 0.050 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 65 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 364 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 2015 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2020 | 205 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 2 | 2011 | 206 | 0.040 |
Why?
|
| Leiomyomatosis | 1 | 2000 | 12 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 57 | 0.040 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1999 | 15 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 149 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 435 | 0.040 |
Why?
|
| Untranslated Regions | 1 | 2019 | 18 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 229 | 0.040 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 1999 | 13 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1999 | 25 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1999 | 39 | 0.040 |
Why?
|
| ROC Curve | 2 | 2014 | 781 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 427 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1999 | 39 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2019 | 119 | 0.040 |
Why?
|
| Immunoassay | 1 | 1999 | 91 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 113 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 1999 | 101 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 307 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 98 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 261 | 0.040 |
Why?
|
| Autoantigens | 1 | 1999 | 129 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 306 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 360 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2007 | 691 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 69 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 57 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 1999 | 151 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 94 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2008 | 1057 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 788 | 0.040 |
Why?
|
| Cryosurgery | 1 | 1998 | 54 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2017 | 69 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 115 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2000 | 260 | 0.040 |
Why?
|
| Incisional Hernia | 1 | 2017 | 17 | 0.040 |
Why?
|
| Prolactinoma | 1 | 1997 | 8 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 2 | 2007 | 16 | 0.040 |
Why?
|
| Hernia, Ventral | 1 | 2017 | 25 | 0.040 |
Why?
|
| Cyclin E | 2 | 2007 | 28 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1998 | 172 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 1997 | 183 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 887 | 0.040 |
Why?
|
| Cyclin B | 2 | 2006 | 18 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 1997 | 115 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 1997 | 31 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2017 | 127 | 0.040 |
Why?
|
| Models, Economic | 1 | 2017 | 62 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 80 | 0.030 |
Why?
|
| Atrophy | 1 | 2017 | 120 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2017 | 105 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 2005 | 3027 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 695 | 0.030 |
Why?
|
| Body Composition | 1 | 2016 | 71 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 784 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 103 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 1999 | 956 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 69 | 0.030 |
Why?
|
| Capecitabine | 1 | 2016 | 98 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 424 | 0.030 |
Why?
|
| Zonula Occludens-2 Protein | 3 | 2000 | 11 | 0.030 |
Why?
|
| Data Collection | 1 | 2017 | 375 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 198 | 0.030 |
Why?
|
| Cystadenoma, Mucinous | 1 | 1995 | 7 | 0.030 |
Why?
|
| Cystadenoma, Serous | 1 | 1995 | 15 | 0.030 |
Why?
|
| Butadienes | 2 | 2005 | 34 | 0.030 |
Why?
|
| RNA Helicases | 1 | 1996 | 35 | 0.030 |
Why?
|
| Flavonoids | 2 | 2006 | 87 | 0.030 |
Why?
|
| Mice | 5 | 2012 | 11761 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 63 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 358 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 102 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 160 | 0.030 |
Why?
|
| Cost Control | 1 | 2015 | 45 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2008 | 815 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Nitriles | 2 | 2005 | 160 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 176 | 0.030 |
Why?
|
| Cystadenoma | 1 | 1994 | 19 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 34 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 33 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 66 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2015 | 83 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 91 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 80 | 0.030 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2014 | 8 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 175 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2016 | 170 | 0.030 |
Why?
|
| Gene Expression | 2 | 2015 | 1310 | 0.030 |
Why?
|
| Mastectomy | 1 | 1996 | 245 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1719 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2016 | 259 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 773 | 0.030 |
Why?
|
| Surgical Mesh | 1 | 2015 | 123 | 0.030 |
Why?
|
| Breast | 1 | 1996 | 292 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 302 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 46 | 0.030 |
Why?
|
| DNA | 2 | 2010 | 1308 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1993 | 41 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2016 | 773 | 0.030 |
Why?
|
| Mammography | 1 | 1996 | 472 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 216 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 1993 | 87 | 0.030 |
Why?
|
| Jejunostomy | 1 | 2012 | 14 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 899 | 0.030 |
Why?
|
| Ligation | 1 | 2012 | 51 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2012 | 25 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2012 | 13 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 1374 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 2012 | 28 | 0.030 |
Why?
|
| Celiac Artery | 1 | 2012 | 25 | 0.030 |
Why?
|
| Immunoblotting | 1 | 1993 | 273 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 447 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2012 | 42 | 0.030 |
Why?
|
| Rats | 3 | 2005 | 4041 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 601 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1237 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2012 | 102 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 48 | 0.020 |
Why?
|
| Cricetinae | 2 | 2005 | 558 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 85 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 217 | 0.020 |
Why?
|
| Adiposity | 1 | 2012 | 76 | 0.020 |
Why?
|
| Mitomycin | 1 | 2011 | 29 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 192 | 0.020 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 103 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 838 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2011 | 67 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2012 | 128 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 282 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1671 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 17 | 0.020 |
Why?
|
| Intestinal Perforation | 1 | 1990 | 36 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 280 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 127 | 0.020 |
Why?
|
| Metaplasia | 1 | 2009 | 37 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2401 | 0.020 |
Why?
|
| Forecasting | 1 | 2011 | 306 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 971 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2009 | 8 | 0.020 |
Why?
|
| CD11 Antigens | 1 | 2009 | 15 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 269 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1990 | 162 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2009 | 90 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 123 | 0.020 |
Why?
|
| Masoprocol | 1 | 2008 | 3 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 96 | 0.020 |
Why?
|
| Thymidine | 1 | 2008 | 59 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 299 | 0.020 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2008 | 6 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 2062 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 10 | 0.020 |
Why?
|
| Pelvic Exenteration | 1 | 2008 | 5 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1668 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 353 | 0.020 |
Why?
|
| Intestinal Fistula | 1 | 2008 | 31 | 0.020 |
Why?
|
| Perineum | 1 | 2008 | 36 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2005 | 1574 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2007 | 11 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2008 | 102 | 0.020 |
Why?
|
| Professional Practice | 1 | 2008 | 46 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 2362 | 0.020 |
Why?
|
| Abdominal Cavity | 1 | 2008 | 18 | 0.020 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2007 | 10 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1990 | 237 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1993 | 805 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 27 | 0.020 |
Why?
|
| Cholestasis | 1 | 2007 | 45 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2010 | 387 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2007 | 25 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 49 | 0.020 |
Why?
|
| Asthenia | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 36 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 46 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2007 | 37 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 51 | 0.020 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2007 | 36 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 465 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 162 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 470 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1987 | 37 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 996 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2001 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2006 | 46 | 0.020 |
Why?
|
| Vagina | 1 | 2008 | 173 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2007 | 77 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2006 | 18 | 0.020 |
Why?
|
| Headache | 1 | 2007 | 72 | 0.020 |
Why?
|
| Maleimides | 1 | 2006 | 26 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 71 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 77 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2006 | 42 | 0.020 |
Why?
|
| Vomiting | 1 | 2008 | 195 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1088 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2008 | 599 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2007 | 698 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2005 | 12 | 0.020 |
Why?
|
| Nitrosamines | 1 | 2005 | 8 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 33 | 0.020 |
Why?
|
| Base Sequence | 2 | 1999 | 2327 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 337 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 269 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 85 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 699 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2006 | 268 | 0.020 |
Why?
|
| Androstadienes | 1 | 2005 | 72 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2005 | 110 | 0.020 |
Why?
|
| Disease Management | 1 | 2007 | 329 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 103 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2005 | 174 | 0.020 |
Why?
|
| Carcinogens | 1 | 2005 | 111 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 911 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 557 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2005 | 73 | 0.020 |
Why?
|
| Quinolines | 1 | 2005 | 91 | 0.020 |
Why?
|
| Random Allocation | 1 | 2005 | 327 | 0.010 |
Why?
|
| Indoles | 1 | 2006 | 314 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 397 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 418 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2005 | 3385 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2007 | 727 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 309 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 345 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 540 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 682 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 983 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2005 | 318 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 645 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 1157 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 605 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2496 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 2002 | 280 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1525 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 1767 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 2884 | 0.010 |
Why?
|
| Vulvar Neoplasms | 1 | 2000 | 20 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1999 | 11 | 0.010 |
Why?
|
| Palpation | 1 | 1999 | 18 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 275 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1999 | 65 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 3018 | 0.010 |
Why?
|
| Introns | 1 | 2000 | 299 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1999 | 258 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 221 | 0.010 |
Why?
|
| Axilla | 1 | 1999 | 104 | 0.010 |
Why?
|
| Exons | 1 | 2000 | 451 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 1242 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 1999 | 108 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 67 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 1185 | 0.010 |
Why?
|
| Gynecomastia | 1 | 1997 | 8 | 0.010 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1997 | 6 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 1997 | 73 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1997 | 511 | 0.010 |
Why?
|
| Recurrence | 1 | 1999 | 1144 | 0.010 |
Why?
|
| RNA, Double-Stranded | 1 | 1996 | 22 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 152 | 0.010 |
Why?
|
| DEAD-box RNA Helicases | 1 | 1996 | 64 | 0.010 |
Why?
|
| eIF-2 Kinase | 1 | 1995 | 48 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 1996 | 200 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1993 | 764 | 0.000 |
Why?
|